Skip to content

Inspection Record

Qingdao Kangyuan Pharmaceutical Co., LTD — FDA 483 Findings

US FDAInspected 2016-04-22Published 2026-11-13 5 findingsEquipment and facilityOther quality systemContamination controlMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

The written procedure, Gauge and Calibration Management, SOP 03-103, version 02, effective date 7/20/15, did not include adequate instructions regarding where a balance should be placed for weighing and measuring operations.

2Other quality system

Th of the ater system is not monitored and now® are installed throughout the system.

3Contamination control

On 4/18/16, we observed an electrical balance, 1D # SC- -|7-04, and a container housing a®® reference weight, 1D # SC-DZC-17-04, sitting on the floor ofthe arehouse@@ which may be subject to contamination and instability.

4Material and supplier control

On 4/18/16, we observed an attachment form, titled “ Balance using records 03-103-A1 02”, which was used to record the weight of materials.@ lL) EE) Crude, on 4/2/16.

5Equipment and facility

The scale, ID # SC-DZC-17-06, which is used in the oom, is@@ calibrated using amo standard weight weighing range is between 0) In addition the vendor calibration certificate dated id not indicate that the scale had been calibrated within the scale weighing range.

A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Qingdao Kangyuan Pharmaceutical Co., LTD findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.